Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Biochemical response of primary biliary cholangitis-autoimmune hepatitis overlap syndrome
induced by ursodeoxycholic acid only or combination therapy of immunosuppressive agents